That was a great summary of the potential impact positive trial results will have on many. It is certainly a must read for the Nuvilex investor.
The best news is that they used cells which grow tumors fast so we should hear something in the near future. Additionally, this gets to patients faster and like you said, some big pharma is or will be paying attention.
I have always believed it will be CELG as they have the most to lose. I also find it interesting that CELG put it to a vote in December of last year do do a stock split. Then Von Hoff, their consultant, contacts us in January wanting to get involved. Once Von Hoff got involved, we started a whole new ball game, all abdominal cancers not just pancreatic cancer. Why all abdominal cancers? I believe it must have something to do with the trials which focus on ascites fluid. I believe Dr Von Hoff was the one interested in taking this approach.
I am feeling very good about my investment. Thanks again, bull, well done!
News 
Market Data 
Discover 
